PDCD1 and extranodal nasal NK/T cell lymphoma: The anti-PD-1 inhibitor sintilimab has shown unique efficacy in refractory relapsed NKTCL-NT, with preliminary results indicating an overall response rate of 67.9%, a complete response rate of 7.1%, and a 1-year overall survival (OS) rate of 82.1% [53].